Leap Therapeutics Reports Second Quarter 2020 Financial Results

CAMBRIDGE, Mass., Aug. 13, 2020 /PRNewswire/ — Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter ended June 30, 2020.
Leap Second Quarter Highlights:

  • Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock
  • Presented updated data for DKN-01 monotherapy that showed a complete response and partia…

    Click here to view the original article.